InSilico Medicine Cayman TopCo (INSILICO) filed its Monthly Return for the period ended 31 July 2026, detailing changes in share capital and equity incentives.

Key figures • Authorised share capital remained unchanged at 1.27 billion ordinary shares with a par value of USD 0.0000005, representing total authorised capital of USD 635. • Issued shares (excluding treasury shares) rose by 6.60 million to 582.44 million. No treasury shares were held or cancelled. • The company confirmed compliance with the minimum public-float threshold of 15 % under Hong Kong listing rules.

Drivers of share issuance • Share-option exercises under pre-IPO equity incentive plans accounted for 4.53 million new shares, generating HKD 32.67 million in cash proceeds. • Restricted Share Units (RSUs) contributed a further 2.07 million shares, split between pre-IPO plans (1.65 million) and the post-IPO RSU scheme adopted on 15 December 2025 (0.42 million).

Outstanding equity incentives • Post-exercise, 20.49 million share options remain outstanding under pre-IPO plans. • The post-IPO share-option scheme holds capacity for up to 24.16 million shares, though none were granted or exercised during the month. • Shares eligible for future issuance under outstanding options and RSUs total 41.39 million.

No warrants, convertible securities, or other share movements were reported for the month.